

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/48, 9/107, 31/565, 31/57		A1	(11) International Publication Number: WO 97/40823
			(43) International Publication Date: 6 November 1997 (06.11.97)
(21) International Application Number: PCT/GB97/01247		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 28 April 1997 (28.04.97)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 9608719.2 26 April 1996 (26.04.96) GB			
(71) Applicant (for all designated States except US): R.P. SCHERER LIMITED [GB/GB]; Frankland Road, Blagrove, Swindon, Wiltshire SN5 8YS (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): PERRY, Elizabeth, Anne [GB/GB]; 1 Copper Beaches, Cricklade Road, Highworth, Swindon, Wiltshire SN6 7BJ (GB). CHANDLER, Susan, Gerrard [GB/GB]; Flat 2, The Old School, 25 River Street, Pewsey, Wiltshire SN9 5DH (GB). FERDINANDO, Josephine, Joan, Christine [GB/GB]; 16 Lytham Close, Monkton Park, Chippenham, Wiltshire SN15 3XW (GB).			
(74) Agent: BOWMAN, Paul, Alan; Lloyd Wise, Tregear & Co., Commonwealth House, 1-19 New Oxford Street, London WC1A 1LW (GB).			
(54) Title: ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING SEX HORMONES			
(57) Abstract <p>A pharmaceutical composition comprising: a hydrophobic drug, a digestible oil selected from triglycerides or propylene glycol esters of medium chain length (C₈-C₁₂) and/or long chain length (C₁₃-C₂₂) fatty acids; and propylene glycol monolaurate, a lipophilic surfactant which comprises a glyceride of a C₅ to C₁₀ fatty acid and a hydrophilic surfactant which is a polyoxyethylene hydrogenated castor oil, wherein the digestible oil is present in an amount on the range from 3.0 to 12.0 % by weight of the composition and the weight ratio of hydrophilic surfactant to lipophilic surfactant is in the range 1:1.5 to 1:2.5. Suitable hydrophobic drugs includes sex hormones such as progesterone, oestradiol and testosterone.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TE	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING SEX HORMONES

This invention relates to pharmaceutical compositions for oral administration and in particular to pharmaceutical compositions comprising sex hormones, such as progesterone, oestradiol and testosterone.

The demand for hormonal preparations to treat menopausal symptoms has been growing rapidly as evidence has accumulated of the benefits of hormone replacement therapy for both symptomatic relief of menopausal symptoms and the prevention of osteoporosis. It is estimated that in the United Kingdom 25% of women suffer from osteoporosis. A preferred treatment for the symptoms and complications of the menopause is a cyclical treatment regimen of an oestrogen alone or a combination of an oestrogen and a progestogen. Most products available, however, contain oestrogens and progestogens from either non-human animal sources or which are synthetic analogues of human hormones.

Progesterone is a naturally occurring female progestogen. Synthetic progestogens have been used for many years as contraceptives and for preventing endometrial hyperplasia in women receiving oestrogens as hormone replacement therapy. Natural progesterone has not been widely used because of its poor oral bioavailability.

Progesterone has traditionally been administered intramuscularly or by the vaginal or rectal route in order to avoid the high rate of "first pass" hepatic metabolism for the drug. Such methods of administration are not universally popular however, and an effective oral dosage form is required. A suspension of micronised progesterone in oil encapsulated in a softgel has recently been available but, as for solid dosage forms, dissolution is still required in vivo and limits the rate of absorption, particularly as the aqueous solubility of progesterone is very low. Gradual dissolution and absorption of progesterone from a suspension provides a

-2-

steady flow of the drug to the liver where it is extensively metabolised, thereby limiting the amount of the dose reaching the systemic circulation. Increasing the rate of drug absorption beyond the rate of metabolism in the liver would be expected to result in increased oral bioavailability.

Testosterone, generally in the form of a testosterone ester, has also been administered therapeutically, e.g. in hormone replacement treatments. Testosterone has been applied by intramuscular injection, implants and orally, e.g. in the form of capsules.

PCT/US90/00721 discloses pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a pharmaceutical compound, an organic solvent and an oil. A solution formulation comprising ethanol, palm oil, polyethylene glycol fatty acid ester, progesterone and N-methyl-2-pyrrolidine (organic solvent) is disclosed. The formulation exhibits improved bioavailability compared to a formulation of micronised progesterone in peanut oil. However, the high quantity of organic solvent present in the formulation is undesirable for use in softgel capsules as it is likely to cause stability problems.

US-A-4963540 discloses pharmaceutical compositions which may be filled in capsules, comprising micronised progesterone in an oil vehicle which is high in glycerides of polyunsaturated fatty acids. It is stated that micronised progesterone particles suspended in such a vehicle are more readily absorbed into the bloodstream than other types of oral progesterone formulations.

WO95/24893 discloses a carrier system for a hydrophobic drug which comprises a digestible oil and a pharmaceutically acceptable surfactant for dispersing the oil in vivo upon administration of the carrier system, said surfactant comprising a hydrophilic surfactant component, and being such that it does not substantially inhibit the lipolysis of the digestible oil. The

-3-

surfactant generally comprises:

(a) a hydrophilic surfactant component which substantially inhibits the in vivo lipolysis of said digestible oil, and

5 (b) a lipophilic surfactant component capable of at least substantially reducing said inhibitory effect of said hydrophilic surfactant component.

The generally preferred range of digestible oil in the carrier system is 10 to 90% with the more preferred
10 range being 20 to 60%, most preferably 25 to 45%.

Several formulations comprising dissolved progesterone are disclosed in which ethanol is present but the maximum concentration of progesterone achieved was 4% by weight. In order to achieve a dose of 50mg of
15 progesterone completely dissolved in the formulation in a softgel capsule it is necessary to employ a large (20 oblong) capsule size or divide the dose into two smaller capsules. Neither of these options is conducive to patient compliance.

20 It has now been found that particular combinations of digestible oil and mixtures of lipophilic and hydrophilic surfactants provide a carrier system which is capable of solubilising significant amounts of hydrophobic drugs, such as, progesterone.

25 According to one aspect of the present invention there is provided a pharmaceutical composition comprising:

a hydrophobic drug,

a digestible oil selected from triglycerides or
30 propylene glycol esters of medium chain length (C_8 - C_{12}) and/or long chain length (C_{13} - C_{22}) fatty acids; and propylene glycol monolaurate,

a lipophilic surfactant which comprises a glyceride of a C_5 to C_{10} fatty acid and

35 a hydrophilic surfactant which is a polyoxyethylene hydrogenated castor oil,
wherein the digestible oil is present in an amount in the

-4-

range from 3.0 to 12.0% by weight of the composition and the weight ratio of hydrophilic surfactant to lipophilic surfactant is in the range 1 : 1.5 to 1 : 2.5.

5 The formulations of the invention allow the drug to be completely solubilised in the liquid formulation. As a solution the drug is presented to the body in the most available form, avoiding the problems of slow
10 disintegration and dissolution associated with other solid oral dosage formulations. This also obviates the need for micronised progesterone and subsequent control of the drug particle size. The formulations may be readily filled in hard or soft capsules.

The blend of digestible oil and surfactants used in the invention provides good solubilisation of the
15 hydrophobic drug. The improved solvent power may be exploited by the formulators in various different ways. It is possible to employ a smaller capsule size to deliver the same drug dose compared with similar formulations in the prior art. Alternatively, or in
20 addition, it is possible to reduce or eliminate ethanol and/or unsaturated compounds, such as maisine, which have been employed in prior art formulations to improve solubilisation of the drug.

The formulations of the invention have been designed
25 to disperse immediately in aqueous environments such as the gastrointestinal tract, forming fine emulsions or microemulsions. In addition, the liquid excipients are chosen such that the emulsified formulation undergoes the natural rapid process of fat digestion (lipolysis). The
30 submicroscopic mixed micelles formed by this process incorporate the products of vehicle lipolysis and solubilised drug. Solubilised drug leaves the microemulsion droplets, the vesicles and the micelles by diffusion. The surface area is vast so the diffusion
35 process is very rapid. Any remaining solubilised drug in the micelles is released when the micelles deaggregate at the intestinal wall. Absorption of progesterone across

-5-

the gastrointestinal wall in association with these mixed micelles is thought to contribute to the increase in drug bioavailability.

Hydrophobic drugs of interest in the present invention are sex hormones, particularly progesterone, oestradiol and testosterone. The invention allows formulations containing in excess of 5% by weight, preferably more than 6% by weight of progesterone in solution to be prepared which allows 50mg dose of progesterone to be encapsulated in softgel capsule, size 12 oblong which is considerably smaller than the size 20 oblong required to deliver 50mg of progesterone in the formulations disclosed in WO95/2493.

Furthermore, the invention allows ethanol to be completely eliminated from the formulations containing hydrophobic drugs. For example, an ethanol free formulation containing progesterone in solution and providing a 25mg dose in a softgel capsule may be formulated and filled into a size 9.5 oblong.

The reference to capsule sizes and shapes herein refer to softgel capsules. The capsule size provides an indication of the nominal fill volume (NFV). Examples of capsule sizes include:

Capsule Size	NFV (minims)	NFV (cm ³)
4	3.0 - 4.0	0.185 - 0.246
9.5	7.5 - 9.5	0.462 - 0.585
20	16 - 20	0.986 - 1.232
10	7.5 - 10.0	0.462 - 0.616
18	15.0 - 18.0	0.924 - 1.109

The compositions of the invention employ smaller amounts of digestible oil than used in W092/24893. Generally 3 to 12%, preferably 4 to 7. The preferred digestible oil is fractionated coconut oil although other digestible oils, such as, peanut oil, soyabean oil,

-6-

propylene glycol monolaurate and propylene glycol ester of fractionated coconut oil which is commercially available under the trade name Miglyol 840 may be used.

5 A blend of hydrophilic and lipophilic surfactants is present in the composition of the invention. The hydrophilic surfactant comprises a polyoxyethylene hydrogenated castor oil, preferably polyoxyethylene (40) hydrogenated castor oil, such as the product commercially available under the trade name Cremophor RH40. The
10 lipophilic surfactant is preferably a mixture of glyceryl mono- and di-caprylate, such as the product commercially available under the trade name Imwitor 988. Other suitable lipophilic surfactants include a mixture of glyceryl mono- and dicaprylates in combination with
15 glyceryl mono- and di-caprylates. Such products are commercially available under the trade names Imwitor 742 and Capmul MCM.

The weight ratio of hydrophilic to lipophilic surfactant is important to achieve optimum solubilisation
20 of the drugs. The weight ratio of hydrophilic to lipophilic surfactant is generally in the range from 1 : 1.5 to 1 : 2.5, usually 1 : 1.7 to 1 : 2.1. For progesterone and oestradiol formulations the ratio is preferably 1 : 1.80 to 1 : 1.90, most preferably about
25 1.85. Testosterone may be used in larger concentrations e.g. 8 to 16% by weight and the preferred weight ratio of hydrophilic to lipophilic surfactant is in the range 1 : 1.7 to 1 : 2.1.

The compositions may additionally comprise a
30 co-solvent, such as ethanol. The presence of ethanol assists in increasing the concentration of drug which may be dissolved thereby allowing smaller volumes of formulation to achieve a desired unit dose. However, the presence of ethanol may result in an increased level of
35 shell-fill interactions in capsules compared to formulations in which ethanol is absent. In addition ethanol can complicate the manufacturing process and

- 7 -

packaging costs can increase where the final package must be impervious to ethanol. Formulations of the invention may be ethanol-free and still provide acceptable dosage levels of drug. The effective ratio of hydrophilic to lipophilic surfactant is not affected by the presence of ethanol.

The formulations of the invention do not require the presence of unsaturated components to solubilise the drug. Thus, compounds, such as Maisine 35-1, which could potentially react with other excipients or the drug itself, may be avoided. Additionally, unsaturated compounds could lead to cross-linking of the gelatin of capsules and ultimately a significantly increased disintegration time, possibly leading to poor adsorption. Preferably, the formulations are free from additives which are unsaturated compounds.

Suitable progesterone formulations containing ethanol in accordance with the invention comprise:

at least 5% by weight of progesterone
40 to 50% by weight of lipophilic surfactants
20 to 30% by weight of hydrophilic surfactants
3 to 10% by weight of digestible oil
15 to 25% by weight of ethanol.

Preferred formulations comprise:

5.5 to 6.5% by weight of progesterone
43 to 45% by weight of lipophilic surfactants
23 to 25% by weight of hydrophilic surfactants
4 to 9 by weight of digestible oil
18 to 20% by weight of ethanol.

A particularly preferred formulation comprises about:

6 parts by weight of progesterone
45 parts by weight of lipophilic surfactants
24 parts by weight of hydrophilic surfactants
4.5 parts by weight of digestible oil
20 parts by weight of ethanol.

Suitable ethanol-free formulations in accordance

-8-

with the invention comprise a pharmaceutical composition comprising:

- from 4 to 5% by weight of progesterone
- 55 to 60% by weight of lipophilic surfactants
- 5 30 to 35% by weight of hydrophilic surfactants
- 3 to 10% by weight of digestible oil.

A preferred formulation comprises about:

- 4.5 parts by weight of progesterone
- 58 parts by weight of lipophilic surfactants
- 10 31.5 parts by weight of hydrophilic surfactants
- 6 parts by weight of digestible oil.

The ethanol-containing and ethanol-free progesterone formulations may additionally comprise from 0.02 to 0.4% oestradiol without substantially altering the ratio of the other components.

The invention also provides ethanol-containing oestradiol formulations comprising:

- 0.05 to 2% by weight of oestradiol
- 45 to 50% by weight of lipophilic surfactants
- 20 22 to 27% by weight of hydrophilic surfactants
- 3 to 10% by weight of digestible oil
- 15 to 25% by weight of ethanol.

A preferred oestradiol formulation comprises about:

- 1 part by weight of oestradiol
- 25 48 parts by weight of lipophilic surfactants
- 26 parts by weight of hydrophilic surfactants
- 5 parts by weight of digestible oil
- 21 parts by weight of ethanol.

Ethanol-free oestradiol formulation in accordance with the invention comprise:

- 0.05 to 2% by weight of oestradiol
- 58 to 62% by weight of lipophilic surfactants
- 30 to 35% by weight of hydrophilic surfactants
- 5 to 7% by weight of digestible oil.

A preferred oestradiol formulation comprises about:

- 1 part by weight oestradiol
- 60 parts by weight of lipophilic surfactants

-9-

33 parts by weight of hydrophilic surfactants
6 parts by weight of digestible oil.

Suitable testosterone formulations in accordance
with the invention comprise:

5 4 to 18% by weight of testosterone
 40 to 48% by weight of lipophilic surfactants
 20 to 25% by weight of hydrophilic surfactants
 7 to 10% by weight of digestible oil
 about 15% by weight of ethanol.

10 The formulations of the invention may comprise minor
amounts of other components e.g. antioxidants.

In all of the above formulations the preferred
components are fractionated coconut oil, Imwitor 988 and
Cremophor RH40.

15 The formulation of the invention spontaneously form
microemulsions when contacted with aqueous media and
maintain the benefits of the composition disclosed in
W095/24893 maintaining lipolysis and bioavailability of
the drug.

20 The composition of the invention may readily be
prepared by known methods, such as described in
W095/24893. The compositions may be encapsulated in
softgel or hardshell capsules. Methods of softgel
encapsulation are disclosed in Theory and Practice of
25 Industrial Pharmacy - Lachman & Leibermann, 2nd Edition,
published by Henry Kimpton Publishers, London. Methods
of liquid-fill hardshell encapsulation are disclosed in
Hardcapsules - Development and Technology - Edited by K.
Ridgeway, published by Pharmaceutical Press 1987.

30 The invention will now be illustrated by the
following Examples.

The formulations reported in the following Tables in
which all figures are in parts by weight were prepared.

-10-

	Example	Comparative Example 5 W095/24893	1	2	3
	Progesterone USP	4.52	5.56	5.56	6.15
5	Imwitor 988	25.79	43.44		45.27
	Imwitor 742			43.44	
10	Cremophor RH40	25.79	23.42	23.42	24.40
	Maisine 35-1	8.60			
	Ethanol USP/BP	18.10	18.89	18.89	19.68
15	Frac. Coconut Oil BP	17.19	8.69	8.69	4.50

	Example	4	5	6	7	8
20	Progesterone USP	4.50				
	Oestradiol USP		1.01	1.01	1.01	1.01
25	Imwitor 988	58.29	47.74	47.73	60.41	60.39
	Cremophor RH40	31.42	25.74	25.73	32.57	32.56
	Ethanol USP/BP		20.76	20.75		
30	Frac. Coconut Oil BP	5.79	4.75	4.75	6.01	6.01
	Tocopherols			0.03		0.03

Example	9	10	11	12	13	14
Oestradiol USP	0.09	0.18	0.06	0.12	0.25	0.045
Progesterone USP	4.50	4.50	6.14	6.14	6.14	4.500
Imwitor 988	58.20	58.11	45.27	45.21	45.15	58.245
Cremophor RH40	31.42	31.42	24.37	24.37	24.34	31.420
Ethanol			19.66	19.66	19.63	
F r a c . Coconut Oil BP	5.79	5.79	4.50	4.50	4.49	5.790

The formulation of each Example comprised stable, solutions of the drug.

The formulations may be filled into softgel capsules to provide a dosage form as follows:

5

10

15

Example	Dose/Capsule	Softgel Capsule Size
Comparative	50mg progesterone	20 oblong
1	50mg progesterone	12 oblong
2	50mg progesterone	12 oblong
3	50mg progesterone	12 oblong
4	25mg progesterone 50mg progesterone	9.5 oblong or 10 oval 18 oblong
5	2mg oestradiol	4 oblong
6	2mg oestradiol	4 oblong
7	2mg oestradiol	4 oblong
8	2mg oestradiol	4 oblong
9	0.5mg oestradiol 25mg progesterone 1mg oestradiol 50mg progesterone	9.5 oblong or 10 oval 18 oblong
10	1mg oestradiol 25mg progesterone	9.5 oblong or 10 oval
11	0.5mg oestradiol 50mg progesterone	12 oblong
12	1mg oestradiol 50mg progesterone	12 oblong
13	2mg oestradiol 50mg progesterone	12 oblong
14	0.5mg oestradiol 50mg progesterone 0.25mg oestradiol 25mg progesterone	18 oblong 9.5 oblong or 10 oval

Relative Rates of Lipolysis

The relative rates of lipolysis for formulations of the Comparative Example and Examples 3 and 4 were measured in accordance with the in vitro test procedure described in W095/24893. The results are reported in Figure 1 of the accompanying drawings which represents a plot of NaOH dispensed against time for the formulations. The composition of the invention, both with and without ethanol indicate effective lipolysis is maintained.

Bioavailability Study

The bioavailability of progesterone from the formulations of the Comparative Example delivered in a 20 oblong softgel capsule and Example 3 delivered in a 12 oblong softgel capsule was measured. The results of the study are reported in Figure 2 of the accompanying drawings which represent a plot of mean serum concentration of progesterone against time for following the administration to 12 subjects of a single oral dose of each softgel capsule containing the progesterone. It will be seen the bioavailability of the formulation of the invention is substantially identical to the Comparative Example.

Examples 15 to 20

The oestradiol formulation reported in the following Table were prepared in which all figures are in parts by weight. All formulations were in the form of solutions of oestradiol.

Example	15	16	17	18	19	20
Oestradiol USP	0.047	0.094	0.188	0.033	0.066	0.132
Inwitor 988	60.993	60.946	60.852	48.197	48.164	48.098
Cremophor RH40	32.900	32.900	32.900	26.000	26.000	26.000
Ethanol USP/BP				20.970	20.970	20.970
Frac. Coconut Oil BP	6.060	6.060	6.060	4.800	4.800	4.800

-14-

The formulations were filled into softgel capsules as follows:

Example 15 0.25mg oestradiol (fill weight of 531mg) in 9.5 oblong or 10 oval capsule.

5 Example 16 0.5mg oestradiol (fill weight of 531mg) in 9.5 oblong or 10 oval capsule.

Example 17 1.0mg oestradiol (fill weight of 531mg) in 9.5 oblong or 10 oval capsule.

10 Example 18 0.25mg oestradiol (fill weight of 763mg) in 12 oblong capsule.

Example 19 0.5mg oestradiol (fill weight of 763mg) in 12 oblong capsule.

Example 20 1.0mg oestradiol (fill weight of 763mg) in 12 oblong capsule.

15 Examples 21 to 38

The following Table, in which all figures are in parts by weight, illustrate testosterone formulations in accordance with the invention. Examples 21 to 26 may be encapsulated to provide a dose of 20mg, Examples 27 to 32 may be encapsulated to provide a dose of 40mg and
20 Examples 33 to 38 may be encapsulated to provide a dose of 80mg.

Example	21	22	23	24	25	26
Testosterone undecanoate	4	4	4	4	4	4
Imwitor 988	46	-	-	46	-	-
Imwitor 742	-	46	-	-	46	-
Capmul MCM	-	-	46	-	-	46
Cremonphor RH40	25	25	25	-	-	-
Tween 80	-	-	-	25	25	25
Miglyol	10	10	10	10	10	10
Ethanol	15	15	15	15	15	15

-15-

Example	27	28	29	30	31	32
Testosterone undecanoate	8	8	8	8	8	8
Imwitor 988	44	-	-	44	-	-
Imwitor 742	-	44	-	-	44	-
Capmul MCM	-	-	44	-	-	44
Cremophor RH40	24	24	24	-	-	-
Tween 80	-	-	-	24	24	24
Miglyol	9	9	9	9	9	9
Ethanol	15	15	15	15	15	15

Example	33	34	35	36	37	38
Testosterone undecanoate	16	16	16	16	16	16
Imwitor 988	41	-	-	41	-	-
Imwitor 742	-	41	-	-	41	-
Capmul MCM	-	-	41	-	-	41
Cremophor RH40	20	20	20	-	-	-
Tween 80	-	-	-	20	20	20
Miglyol	8	8	8	8	8	8
Ethanol	15	15	15	15	15	15

CLAIMS

1. A pharmaceutical composition comprising:
a hydrophobic drug,
a digestible oil selected from triglycerides or
5 propylene glycol esters of medium chain length (C_8 - C_{12})
and/or long chain length (C_{13} - C_{22}) fatty acids; and
propylene glycol monolaurate,
a lipophilic surfactant which comprises a glyceride
of a C_5 to C_{10} fatty acid and
10 a hydrophilic surfactant which is a polyoxyethylene
hydrogenated castor oil,
wherein the digestible oil is present in an amount in the
range from 3.0 to 12.0% by weight of the composition and
the weight ratio of hydrophilic surfactant to lipophilic
15 surfactant is in the range 1 : 1.5 to 1 : 2.5.
2. A pharmaceutical composition as claimed in Claim 1
in which the hydrophobic drug is dissolved and is
selected from progesterone, oestradiol, testosterone and
mixture of progesterone and oestradiol.
- 20 3. A pharmaceutical composition comprising:
at least 5% by weight of progesterone
40 to 50% by weight of lipophilic surfactants
20 to 30% by weight of hydrophilic surfactants
3 to 10% by weight of digestible oil
25 15 to 25% by weight of ethanol.
4. A pharmaceutical composition as claimed in Claim 3
comprising:
5.5 to 6.5% by weight of progesterone
43 to 45% by weight of lipophilic surfactants
30 23 to 25% by weight of hydrophilic surfactants
4 to 9% by weight of digestible oil
18 to 20% by weight of ethanol.

-17-

5. A pharmaceutical composition as claimed in Claim 4 comprising about:

5 6 parts by weight of progesterone
 45 parts by weight of lipophilic surfactants
 24 parts by weight of hydrophilic surfactants
 4.5 parts by weight of digestible oil
 20 parts by weight of ethanol.

6. A pharmaceutical composition comprising:

10 4 to 5% by weight of progesterone
 55 to 60% by weight of lipophilic surfactants
 30 to 35% by weight of hydrophilic surfactants
 3 to 10% by weight of digestible oil.

7. A pharmaceutical composition as claimed in Claim 6 comprising about:

15 4.5 parts by weight of progesterone
 58 parts by weight of lipophilic surfactants
 31.5% parts by weight of hydrophilic surfactants
 6% parts by weight of digestible oil.

8. A pharmaceutical composition as claimed in any one
20 of Claims 3 to 7 which additionally comprises from 0.02 to 2.0% oestradiol.

9. A pharmaceutical composition comprising:

 0.05 to 2% by weight of oestradiol
 45 to 50% by weight of lipophilic surfactants
25 22 to 27% by weight of hydrophilic surfactants
 3 to 10% by weight of digestible oil
 15 to 25% by weight of ethanol.

10. A pharmaceutical composition as claimed in Claim 9 comprising about:

30 1 part by weight of oestradiol
 48 parts by weight of lipophilic surfactants
 26 parts by weight of hydrophilic surfactants
 5 parts by weight of digestible oil
 21 parts by weight of ethanol.

35


-18-


11. A pharmaceutical composition comprising:
0.05 to 2% by weight of oestradiol
58 to 62% by weight of lipophilic surfactants
30 to 35% by weight of hydrophilic surfactants
5 to 7% by weight of digestible oil.
12. A pharmaceutical composition as claimed in Claim 11 comprising about:
1 part by weight oestradiol
60 parts by weight of lipophilic surfactants
33 parts by weight of hydrophilic surfactants
6 parts by weight of digestible oil.
13. A pharmaceutical composition comprising:
4 to 18% by weight of testosterone
40 to 48% by weight of lipophilic surfactants
20 to 25% by weight of hydrophilic surfactants
7 to 10% by weight of digestible oil
about 15% by weight of ethanol.
14. A pharmaceutical composition as claimed in any preceding claim in which the digestible oil is fractionated coconut oil.
15. A pharmaceutical composition as claimed in any preceding Claim in which the lipophilic surfactant comprises a mixture of glyceryl mono- and di-caprylate.
16. A pharmaceutical composition as claimed in Claim 15 in which the lipophilic surfactant additionally comprises a mixture of glyceryl mono- and di-caprate.
17. A pharmaceutical composition as claimed in any preceding Claim in which the hydrophilic surfactant comprises polyoxyethylene (40) hydrogenated castor oil.
18. A pharmaceutical composition as claimed in Claim 1 or Claim 2 which additionally comprises up to 25% by weight of the composition of ethanol.
19. A pharmaceutical composition as claimed in any preceding Claim in which the weight ratio of hydrophilic surfactants to lipophilic surfactants is in the range 1 : 1.5 to 1 : 2.5.

20. A pharmaceutical composition as claimed in Claim 18 in which the weight ratio of hydrophilic surfactants to lipophilic surfactants is in the range 1 : 1.80 to 1 : 1.90.
21. A pharmaceutical composition as claimed in Claim 19 in which the weight ratio of hydrophilic surfactants to lipophilic surfactants is about 1 : 1.85.
22. A pharmaceutical composition as claimed in Claim 1 or Claim 2 which is free of ethanol.
23. A pharmaceutical composition as claimed in Claim 1 or Claim 2 which is free of additives which are unsaturated compounds.
24. A hard or soft capsule filled with a pharmaceutical composition as claimed in any preceding Claim.
25. A softgel capsule as claimed in Claim 24 comprising a capsule of size 12 oblong containing 50mg of progesterone.
26. A softgel capsule as claimed in Claim 24 comprising a capsule of size 9.5 oblong or 10 oval containing 25mg progesterone in an ethanol-free formulation.
27. A softgel capsule as claimed in Claim 25 or Claim 26 in which the capsule additionally contains from 0.25 to 2mg of oestradiol.
28. A softgel capsule as claimed in Claim 24 containing from 20 to 80mg testosterone.

1/2

FIGURE 1





INTERNATIONAL SEARCH REPORT

In .tional Application No
PCT/GB 97/01247

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/48 A61K9/107 A61K31/565 A61K31/57

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 95 24893 A (R.P. SCHERER LIMITED) 21 September 1995 cited in the application</p> <p>see the whole document -----</p>	<p>1-3,6, 12, 14-17, 19-21, 24-26</p>

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

22 August 1997

Date of mailing of the international search report

01.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Ventura Amat, A

Information on patent family members

PCT/GB 97/01247

Form PCT/ISA/210 (patent family annex) (July 1992)

